279 related articles for article (PubMed ID: 28964439)
1. Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates.
Chen CX; Baker JR; Nichol MB
Value Health; 2017 Sep; 20(8):1074-1082. PubMed ID: 28964439
[TBL] [Abstract][Full Text] [Related]
2. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States.
Zhou ZY; Koerper MA; Johnson KA; Riske B; Baker JR; Ullman M; Curtis RG; Poon JL; Lou M; Nichol MB
J Med Econ; 2015 Jun; 18(6):457-65. PubMed ID: 25660324
[TBL] [Abstract][Full Text] [Related]
3. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
4. Costs and utilization of treatment in patients with hemophilia.
Rocha P; Carvalho M; Lopes M; Araújo F
BMC Health Serv Res; 2015 Oct; 15():484. PubMed ID: 26502954
[TBL] [Abstract][Full Text] [Related]
5. Costs and utilization of hemophilia A and B patients with and without inhibitors.
Armstrong EP; Malone DC; Krishnan S; Wessler MJ
J Med Econ; 2014 Nov; 17(11):798-802. PubMed ID: 25111634
[TBL] [Abstract][Full Text] [Related]
6. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys.
Burke T; Asghar S; O'Hara J; Sawyer EK; Li N
Orphanet J Rare Dis; 2021 Mar; 16(1):143. PubMed ID: 33743752
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
8. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.
Shapiro AD; Donfield SM; Lynn HS; Cool VA; Stehbens JA; Hunsberger SL; Tonetta S; Gomperts ED;
Pediatrics; 2001 Dec; 108(6):E105. PubMed ID: 11731632
[TBL] [Abstract][Full Text] [Related]
9. The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults.
Chandran A; Schaefer C; Ryan K; Baik R; McNett M; Zlateva G
J Manag Care Pharm; 2012; 18(6):415-26. PubMed ID: 22839682
[TBL] [Abstract][Full Text] [Related]
10. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Thorat T; Neumann PJ; Chambers JD
J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
[TBL] [Abstract][Full Text] [Related]
11. [Survey of economic burden of hepatitis B-related diseases in 12 areas in China].
Ma QS; Liang S; Xiao HW; Zhang SX; Zhuang GH; Zou YH; Tan HZ; Liu JC; Zhang YH; Xu AQ; Zhang L; Feng XX; Hu DS; Wang FZ; Cui FQ; Liang XF
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):868-876. PubMed ID: 28738457
[No Abstract] [Full Text] [Related]
12. Hemophilia in the managed care setting.
Dalton DR
Am J Manag Care; 2015 Mar; 21(6 Suppl):S123-30. PubMed ID: 26168207
[TBL] [Abstract][Full Text] [Related]
13. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
14. Association between physical activity and risk of bleeding in children with hemophilia.
Broderick CR; Herbert RD; Latimer J; Barnes C; Curtin JA; Mathieu E; Monagle P; Brown SA
JAMA; 2012 Oct; 308(14):1452-9. PubMed ID: 23047359
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of seasonal influenza in the United States.
Putri WCWS; Muscatello DJ; Stockwell MS; Newall AT
Vaccine; 2018 Jun; 36(27):3960-3966. PubMed ID: 29801998
[TBL] [Abstract][Full Text] [Related]
16. BE EMPOWERED, a specialty pharmacy education program for hemophilia B patients, impacts adult joint bleeds and pediatric use of RICE.
Blankenship CS; Tortella BJ; Bruno M
J Manag Care Pharm; 2014 Feb; 20(2):151-8. PubMed ID: 24456316
[TBL] [Abstract][Full Text] [Related]
17. [Economic impact of hemophilia type A and B in Mexico].
Carlos-Rivera F; Gasca-Pineda R; Majluf-Cruz A; García-Chávez J
Gac Med Mex; 2016; 152(1):19-29. PubMed ID: 26927640
[TBL] [Abstract][Full Text] [Related]
18. [Economic cost of treating the patient with asthma in Spain: the AsmaCost study].
Martínez-Moragón E; Serra-Batllés J; De Diego A; Palop M; Casan P; Rubio-Terrés C; Pellicer C;
Arch Bronconeumol; 2009 Oct; 45(10):481-6. PubMed ID: 19525051
[TBL] [Abstract][Full Text] [Related]
19. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.
Miners AH; Sabin CA; Tolley KH; Lee CA
J Intern Med; 1998 Dec; 244(6):515-22. PubMed ID: 9893105
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of hemophilia A and B: a case in Iran.
Keshavarz K; Bordbar M; Hashemipoor Z; Jalali FS; Ravangard R
Hematology; 2020 Dec; 25(1):149-155. PubMed ID: 32249720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
